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The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is a vaccine immunogen that can
signal via several cell surface receptors. To investigate whether receptor biology could influence immune responses to
gp120, we studied its interaction with human, monocyte-derived dendritic cells (MDDCs) in vitro. Gp120 from the HIV-1
strain JR-FL induced IL-10 expression in MDDCs from 62% of donors, via a mannose C-type lectin receptor(s) (MCLR).
Gp120 from the strain LAI was also an IL-10 inducer, but gp120 from the strain KNH1144 was not. The mannose-
binding protein cyanovirin-N, the 2G12 mAb to a mannose-dependent gp120 epitope, and MCLR-specific mAbs
inhibited IL-10 expression, as did enzymatic removal of gp120 mannose moieties, whereas inhibitors of signaling via
CD4, CCR5, or CXCR4 were ineffective. Gp120-stimulated IL-10 production correlated with DC-SIGN expression on the
cells, and involved the ERK signaling pathway. Gp120-treated MDDCs also responded poorly to maturation stimuli by
up-regulating activation markers inefficiently and stimulating allogeneic T cell proliferation only weakly. These
adverse reactions to gp120 were MCLR-dependent but independent of IL-10 production. Since such mechanisms might
suppress immune responses to Env-containing vaccines, demannosylation may be a way to improve the
immunogenicity of gp120 or gp140 proteins.
Citation: Shan M, Klasse PJ, Banerjee K, Key AK, Iyer SPN, et al. (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3(11):
e169. doi: 10.1371/journal.ppat.0030169
Introduction
One approach to a vaccine against HIV-1 is the use of the
viral envelope glycoproteins (Env) as immunogens to induce
neutralizing antibodies (NAbs) [1–3]. Usually, the Env glyco-
proteins are presented as adjuvanted, soluble proteins after
production in vitro as recombinant proteins, but they can also
be expressed in vivo from delivery systems based on DNA or
live recombinant viruses (e.g., poxvirus or adenovirus vectors)
[4]. Different conﬁgurations of Env glycoproteins have been
studied as vaccine antigens, initially the surface glycoprotein
gp120; more recently, soluble oligomeric gp140 proteins
based broadly on the native gp120-gp41 complex [1–3].
Irrespective of how HIV-1 Env glycoproteins have been
presented and in whatever conﬁguration, the induction of
broadly active NAbs has proven problematic [1]. One
generally accepted problem is the evolution of the native
Env complex into a conﬁguration that limits the exposure of
the few neutralization sites that are present. The potential
solution is to further understand the structure of the
complex, then to engineer antigens that are better able to
present relevant NAb epitopes to the immune system;
attempts to do this are in progress in many laboratories
worldwide [1]. Here, however, we focus on what we consider
to be another factor hindering NAb induction: the limited
immunogenicity of HIV-1 Env proteins in general.
Although antibody responses to HIV-1 Env can clearly be
induced in infected or vaccinated humans and animals, these
proteins are not particularly immunogenic. Thus, gp120 or
gp140 proteins are typically administered at 100–500 lg per
dose, and the binding antibody titers raised against them can
be highly variable; some humans and animals respond fairly
well, others only poorly [5–9]. Anti-Env antibody titers also
decay rather rapidly (half-lives are typically in the range 30–
50 d) and frequent boosting is required to maintain them.
Few directly comparative studies have ever been performed,
but the limited information available supports the contention
that Env is an unusually problematic immunogen compared
to most other vaccine antigens [10] (S. Plotkin and B. Graham,
personal communication).
The immune responses to HIV-1 Env vaccine antigens are
TH2-polarized to an extent that is unusual even for a soluble
protein [11,12]. The same TH2 bias can also be observed during
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controversial situation [13–15]. The nature of the immune
response to gp120 may be attributable to the fundamental
properties of this unusual protein. One feature that distin-
guishes gp120 from many other vaccine immunogens is its
biological activity; gp120 can bind to several cell surface
receptors: CD4, CCR5, CXCR4, and several mannose C-type
lectin receptors (MCLR) including but not limited to DC-SIGN
[2]. In vitro, one consequence of gp120 binding to such
receptors is the transduction of intracellular signals that can
have many different, but generally adverse, effects on the
various target cells. Although the gp120 concentrations used to
elicit such signals (lg/ml range) are usually grossly in excess of
what could be present in serum during HIV-1 infection [16],
theyarecompatiblewithwhatisusedforimmunization(several
hundred lg of protein delivered in a few ml into a localized
tissue site) [5–9].Wetherefore considereditpossible that gp120
immunization could trigger signals affecting how an immune
response develops. For example, one cellular response to gp120
invitroistheinductionofIL-10,ananti-inﬂammatorycytokine
[17–24]. Here, we have studied what happens when gp120
interacts with human monocyte-derived dendritic cells
(MDDCs) in vitro. We show that a consequence of JR-FL
gp120 binding to these cells from ;50% of donors is the
induction of IL-10. Moreover, gp120-treated MDDCs impair
the proliferation of co-cultured CD4
þ T cells and reduce their
expression of IL-12. These responses are also a consequence of
the mannose-dependent interaction of gp120 with an MCLR,
although they are not obligatorily linked to IL-10 expression.
The various outcomes of gp120-MCLR interactions are
prevented by enzymatic removal of gp120 mannoses, a method
that may improve the immunogenicity of HIV-1 Env proteins
and some other vaccine-relevant immunogens.
Results
HIV-1 gp120 Induces MDDCs to Produce IL-10
We investigated how gp120 affected MDDC maturation
and cytokine secretion, and MDDC-T cell interactions in view
of the key role dendritic cells (DCs) play in antigen capture,
processing, and presentation. The preparation and proper-
ties of the MDDCs are described under Supporting Informa-
tion (Figure S1). We were particularly interested to ascertain
whether gp120 induced IL-10 expression in MDDCs, in view
of the immunosuppressive effects of IL-10 and its role in
TH2-polarization of responses to gp120 in immunized mice
[11], and the induction of IL-10 by gp120 in human
monocyte/macrophages in vitro [17,18,20,22,24]. We there-
fore used MDDCs that were immature at the start of the
experiment (iMDDCs), to enable us to monitor the subse-
quent maturation process. However, in some studies, we
investigated the effects of gp120 on MDDC that were
simultaneously induced to mature by other stimuli, notably
lipopolysaccharide (LPS).
iMDDCs from a day-6 culture were washed thoroughly to
prevent further stimulation with IL-4 and GM-CSF, then
incubated for two further days with or without CHO-cell
expressed, JR-FL (R5) gp120 (the 3 lg/ml; 25 nM concen-
tration was based on titrations in pilot studies; see below). In
the absence of any stimulus, the cells produced little IL-10
(mean 11 6 2.5 pg/ml at 24 h, n¼71 and 28 6 3.8 pg/ml at 48
h, n ¼ 52) and no detectable IL-12p70 over a 48-h period
starting on day 6. The addition of JR-FL gp120 triggered
signiﬁcant IL-10 secretion from MDDCs from a subset of the
71 blood donors (Figure 1A). Thus, 24 h later, IL-10
production was increased by .5-fold in MDDCs from 62%
(44/71) donors, with the median increase being 8.5-fold
(median control value: 7.5 pg/ml; median þ gp120, 64 pg/
ml). Similar responses were observed at 48 h (median control
value: 17 pg/ml; þ gp120, 98 pg/ml). The IL-10 increases
triggered by gp120 were signiﬁcant at both 24 h and 48 h
(Mann-Whitney U test, one tail, p , 0.0001). However,
MDDCs from 38% of the donors did not respond to gp120
(IL-10 increases of ,5-fold).
Although a subset was unresponsive to gp120, day-6
iMDDCs from every donor reacted to the classic TNIL þ
LPS (þCD40L when IL-12p70 was analyzed) maturation
stimulus by producing high levels of both IL-10 (mean 1,639
6 665 pg/ml, n ¼ 71) and IL-12p70 (mean 235 6 56 pg/ml, n
¼ 12) over a 48-h period (Figure 1A and unpublished data).
The median fold-increase in IL-10 production in response to
TNIL þ LPS after 24 h was 149-fold, 17.5 times greater than
the median response to gp120. The IL-10 responses to TNILþ
LPS and to gp120 did not correlate (at 24 h, n¼71, r
2¼0.0007
and at 48 h, n¼12, r
2¼0.006, respectively). The time courses
of the IL-10 responses to JR-FL gp120, at both the mRNA and
protein levels, and to TNIL þ LPS at the mRNA level, are
shown as Figure S2.
The donor-dependent variation in the IL-10 response to
gp120 could be explained by genetic or epigenetic factors. As a
ﬁrst step to determining which applied, we performed experi-
ments on MDDCs from 11 repeat donors, at two time points, 1–
3 months apart. An IL-10 response to gp120 was observed in
MDDCsfromfourofthe11donorsatbothtimepoints,whereas
there was no response at either time point from cells of the
othersevendonors(Figure1B).Theconsistency oftheresponse
pattern is more suggestive of a genetic or a constant epigenetic
determinant than of a variable epigenetic factor such as, for
example, an inter-current infection.
IL-10 secretion by MDDCs from responsive donors was
dependent on the concentration and the identity of the
gp120 protein used (Figure 1C). The optimal response to JR-
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Author Summary
Dendritic cells (DCs) initiate immune responses to pathogens or
vaccine antigens. The HIV-1 gp120 envelope glycoprotein is an
antigen that is a focus of vaccine design strategies. We have studied
how gp120 proteins interact with DCs in cell culture. Certain gp120s
stimulate DCs from some, but not all, human donors to produce IL-
10, a cytokine that is generally immunosuppressive. In addition,
whether or not the DCs produce IL-10, their ability to mature
properly when activated is impaired by gp120—the gp120-treated
DCs have a reduced ability to stimulate T cell growth when the two
cell types are cultured together. These various effects of gp120 are
caused by its binding to cell surface receptors of the mannose C-
type lectin receptor family, including (but probably not exclusively)
one called DC-SIGN. Gp120 binds to these receptors via mannose
residues that are present on some of the glycan structures that
overlay much of its protein surface. Removing the mannoses by
digesting gp120 with a suitable enzyme prevents IL-10 induction
and impairment of DC maturation, as does the use of inhibitors of
the binding of gp120 to DC-SIGN and similar receptors. This work
could help with the design of better HIV-1 vaccines.FL gp120 occurred at 3 lg/ml, whereas the dose-response
curve for LAI gp120 was slightly different, IL-10 secretion
being greatest at 10 lg/ml, the highest concentration tested.
However, when MDDCs from the same donors were exposed
to gp120 from the subtype A virus KNH1144, there was no
IL-10 response (Figure 1C). Furthermore, when MDDCs
from ﬁve donors were tested comparatively, the same three
that responded to JR-FL gp120 also did so to LAI gp120, and
to similar extents, whereas MDDCs from all ﬁve donors
responded to TNIL þ LPS by producing high levels of IL-10
(Figure 1D). Hence both viral and host genetics may
inﬂuence whether MDDCs produce IL-10 after exposure to
gp120. We determined the viability of iMDDCs and mature
MDDCs (mMDDCs) exposed for 48 h to the three different
gp120s by staining with 7 amino-actinomycin D. Sponta-
neous cell death in cultures from different donors varied
from 2%–3% in iMDDCs and 3%–12% in mMDDCs. The
additional death of iMDDCS or mMDDCS measured in the
presence of up to 10 lg/ml of JR-FL gp120, with or without
demannosylation (see below), was ,7%; for LAI gp120, it
was ,5% at up to 20 lg/ml; for KNH1144 gp120 it was ,5%
at up to 10 lg/ml.
The JR-FL, LAI, and KNH1144 proteins used in Figure 1C
were all manufactured under good manufacturing process
Figure 1. HIV-1 gp120 Induces IL-10 Secretion from MDDCs in a Donor- and Concentration-Dependent Manner
(A) MDDCs from different human donors were cultured in GM-CSF þ IL-4 for 6 d and then incubated for 24 h (n ¼ 71 donors) with or without JR-FL
gp120 (3 lg/ml) before measurement of IL-10 production by ELISA. The fold-increases in IL-10 production after gp120 treatment compared with
untreated cells are depicted on the y-axis. Another set of MDDC from each donor was stimulated for 24 h with TNILþLPS (6CD40L), instead of gp120.
The corresponding fold-increase in IL-10 secretion compared with untreated cells is also plotted.
(B) MDDCs from 11 pedigreed donors were cultured and stimulated with gp120 or TNILþLPS, as in (A), twice within a 3-mo interval. IL-10 production
was measured 24 h after stimulation. Black bars represent the first assay on each donor, white bars the second.
(C) The secretion of IL-10 from iMDDCs after 24 h is depicted as a function of the gp120 concentration. The data points show mean values 6 SD (the
error bars lie within the symbols) of duplicate ELISA determinations. Each curve represents data derived from a single donor, the same symbol
representing the same donor in each panel. Left: Three different donors, JR-FL gp120. Middle: Four different donors, LAI gp120. Right: Three different
donors, KNH1144 gp120 (the square symbol is overlaid by the circle symbol).
(D) iMDDCs from five donors were treated with JR-FL gp120 (3 lg/ml), LAI gp120 (10 lg/ml), KNH1144 gp120 (10 lg/ml), or TNIL þ LPS before
measurement of IL-10 production at 24 h.
doi:10.1371/journal.ppat.0030169.g001
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additional gp120 proteins of different genotypes and expressed
in different cell types (including insect cells) that we obtained
from commercial sources and academic collaborators. In
general, the degree ofLPS contamination inthesepreparations
was too high for the results to be interpretable, since LPS is
itselfa highly efﬁcient inducer ofIL-10 fromMDDCs (Figure 1).
HIV-1 gp120 Stimulates IL-10 Production by MDDCs
through a Mannose-Dependent Interaction
To determine which gp120 receptors on iMDDCs were
responsible for activating IL-10 expression, we incubated
either gp120 or the cells with ligands that should block known
gp120-receptor interactions (Figures 2A, S3, and S4). Neither
Figure 2. The Induction of IL-10 Secretion by gp120 Is Mannose-Dependent
(A) The bars represent IL-10 production from MDDCs on day 6 after 24 h (black bars) of treatment with JR-FL gp120 (3 lg/ml). The reagents listed on the
horizontal axis were incubated with gp120 or iMDDCs for 1 h prior to addition of gp120 to the cells (see Materials and Methods for the inhibitor
concentrations tested). The bars represent the mean value 6 SEM for data derived from five different, gp120-responsive donors. The left and right
panels show data derived from different experiments. The various reagents were also tested in the absence of gp120 and found not to stimulate IL-10
production (,25 pg/ml, unpublished data), with the exception of mannan (see right panel).
(B) The reactivities of mAbs b12 and 2G12, the CD4-IgG2 protein, or DC-SIGN-Fc with mock-treated JR-FL M-gp120 (squares) and a-(1,2,3,6)
mannosidase-treated JR-FL D-gp120 (circles) were compared using ELISAs. In the fifth panel, the binding of DC-SIGN-Fc to JR-FL gp120 was inhibited by
the Ca
2þ-chelator EGTA and the anti-DC-SIGN mAb, AZN-D1 (M-gp120 black bar; D-gp120 white bar).
(C) Left panel: A reducing SDS-PAGE gel shows the reduction in JR-FL gp120 m.wt. caused by treatment with a-(1,2,3,6) mannosidase. Right panel:
western blotting with anti-gp120 serum ARP3119 confirms the m.wt reduction, and blotting with mAb 2G12 shows that its mannose-dependent
epitope has been removed from gp120. (M ¼ m.wt markers; enzyme only ¼ no gp120 present).
(D) The experimental design was the same as in (A). The gp120 proteins (or influenza HA or TNILþLPSþCD40L) tested are listed on the x-axis. The bars
represent the mean values 6 SEM for data derived from five different donors (black bars, IL-10 production after 24 h; white bars, after 48 h).
doi:10.1371/journal.ppat.0030169.g002
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inhibited IL-10 production, implying that a gp120-CD4
interaction was not responsible. The small-molecule CCR5
antagonist AD101 was not inhibitory, ruling out signals
transduced via gp120-CCR5 binding (Figure S4). The CXCR4
antagonist AMD3100 was inactive against IL-10 induction by
gp120 from the X4 virus, LAI, so CXCR4 is also uninvolved
(unpublished data). As expected, AMD3100 did not inhibit
the IL-10 response to JR-FL gp120, or AD101 the response to
LAI gp120 (Figure S4 and unpublished data). In contrast,
when gp120 was pre-treated with either mAb 2G12 or CV-N,
IL-10 induction was strongly inhibited (Figure 2A). Both 2G12
and CV-N bind to mannose moieties on gp120 N-linked
glycans [25–27], implicating an interaction between gp120
and an MCLR(s) as the critical trigger for IL-10 induction. We
also tested whether soluble mannans antagonized gp120-
dependent IL-10 expression, but found that mannans
themselves strongly activated an IL-10 response (Figure 2A).
However, combining gp120 with mannans did not further
elevate IL-10 levels, suggesting that both of these mannose-
containing ligands bind to, and saturate, the same MCLR(s).
To explore which MCLR(s) might be involved, we used mAbs
speciﬁc to DC-SIGN and the mannose receptor (MR). The
anti-DC-SIGN mAb AZN-D1 completely blocks the binding of
mannosylated gp120 to DC-SIGN in an ELISA (Figure 2B).
Two mAbs to DC-SIGN, including AZN-D1 and mAb Clone
19 to the MR, can each reduce the binding of gp120 to a
subset of tonsillar B cells [28]. When the anti-DC-SIGN and
anti-MR mAbs AZN-D1 and Clone 15–2 were each pre-
incubated with iMDDCs, AZN-D1 partially (;50%) reduced
gp120-mediated IL-10 induction whereas Clone 15–2 was not
inhibitory; adding the two mAbs together completely
abolished the IL-10 response (Figure 2A). An anti-CD4 mAb
was not inhibitory by itself at 24 h and did not affect the
actions of the anti-MCLR mAbs when combined with them,
although it did cause partial (45% 6 SD 29%) inhibition at 48
h (Figure 2A and unpublished data). Other than mannan, the
various mAbs and ligands described above did not induce IL-
10 expression or block LPS-induced IL-10 expression (Figures
2A, S4, and unpublished data). The same concentrations (40
lg/ml) of different murine isotype control antibodies, alone
and in combination, were also without effect (Figure S4 and
unpublished data).
The above experiments imply that MCLRs, particularly but
probably not only DC-SIGN, are the gp120 receptors that
trigger the IL-10 response. If so, the high mannose residues
on gp120 glycans are likely to be the cognate ligands. To
prove this, the mannose moieties were removed from gp120
by enzymatic digestion with a-(1,2,3,6)-mannosidase [25].
Reducing SDS-PAGE gel analysis showed the demannosylated
JR-FL gp120 (D-gp120) was slightly smaller than mock-treated
gp120 (M-gp120; processed without the enzyme) and had lost
its 2G12 epitope (Figure 2C; compare lanes marked þand  ).
The successful removal of mannose was veriﬁed by showing
that D-gp120 failed to bind either 2G12 or DC-SIGN-Fc in
ELISAs, in contrast to M-gp120 (Figure 2B). However, both
mAb b12 and CD4-IgG2 bound efﬁciently to structures
associated with the CD4-binding site on D-gp120 (Figure
2B), showing that JR-FL gp120 was efﬁciently demannosylated
without impairing its overall conformation [25,27]. Hence we
could now directly assess the role of the high mannose glycans
in the IL-10 response.
M-gp120 induced substantial IL-10 production (150–300
pg/ml) from MDDCs from ﬁve different donors, whereas D-
gp120 had no such effect. Inﬂuenza virus HA did not
stimulate IL-10 production, whereas TNIL þ LPS activated a
strong response (Figure 2D). An interaction between the
mannose moieties on gp120 and an MCLR(s) can therefore
trigger IL-10 production from MDDCs from a signiﬁcant
proportion of human donors. The lack of effect of HA, which
does not bind to DC-SIGN, compared to gp120 is consistent
with the outcome of comparative immunization studies with
these two viral receptor-binding glycoproteins in mice [11].
The blocking effect of the anti-DC-SIGN and anti-MR mAb
combination implicated these MCLRs as likely mediators of
the IL-10 response to gp120 (Figure 2A). Because this
response is donor-dependent (Figure 1A), we measured DC-
SIGN and MR expression on day-6 iMDDCs (the time of
addition of gp120) from nine donors, as well as the expression
of CD80, CD83, and CD86. DC-SIGN levels varied by 18-fold
among these nine donors, MR by 3.3-fold (in studies of other
sets of donors, we have found that the expression levels of
both these receptors can vary by about an order of
magnitude; unpublished data). The IL-10 response to JR-FL
gp120 correlated with the level of DC-SIGN expression on
day 6 (n¼9, r
2¼0.52, p¼0.028) but not with MR expression (n
¼9, r
2¼ 0.19, p ¼ 0.25). Moreover, there were no correlations
between IL-10 production and the expression of CD80 (n¼9,
r
2¼0.052, p¼0.59), CD83 (n¼9, r
2¼0.33, p¼0.14), or CD86 (n
¼9, r
2 ¼0.27, p ¼0.19). Thus, of the ﬁve correlations with IL-
10 production that we performed, the only substantial one
was with DC-SIGN expression.
HIV-1 gp120 Induces IL-10 Production via the ERK
Signaling Pathway
We next sought to identify which signaling pathway(s) was
involved in the upregulation of IL-10 expression after the
gp120-MCLR interaction. We focused on the ERK1/2 and p38
MAP kinase pathways [29], because ERK1/2 phosphorylation
and activation promotes IL-10 production and inhibits IL-12
production by DC [30], whereas inhibition of ERK1/2
activation has the opposite effects [31]. Conversely, p38
mediates the induction of IL-12p70 expression by LPS [29].
Furthermore, DC-SIGN ligation by antibodies can lead to
ERK1/2 phosphorylation [32]. We observed that TNIL þ LPS
strongly activated the phosphorylation of both ERK1/2 and
p38 within 5 min, effects that persisted for 30–60 min (Figure
3A and unpublished data). A lesser, but still signiﬁcant, level
of ERK1/2 activation occurred after 5–10 min in MDDCs
treated with M-gp120, ERK1/2 phosphorylation levels then
declining back to baseline after 30 min. However, there was
no detectable phosphorylation of p38 in response to M-gp120
at any time point (Figure 3A and unpublished data). D-gp120,
in contrast, failed to activate the phosphorylation of either
ERK1/2 or p38 (Figure 3A), implying that the gp120-MCLR
interaction leads to the speciﬁc, albeit transient, activation of
the ERK1/2 signaling pathway. In the same experiment, M-
gp120, but not D-gp120, induced modest levels of IL-10
production, whereas TNIL þ LPS þ CD40L activated a much
greater IL-10 response (Figure 3B), observations in propor-
tion to the levels of ERK1/2 activation induced by the
different stimuli (Figure 3A).
We used signaling inhibitors to determine whether there is
a link between ERK1/2 activation and IL-10 production.
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or 10 lM SB 203580 (a p38 MAP kinase inhibitor) for 1–2 h,
then IL-10 and IL-12p70 production in response to JR-FL M-
gp120 or TNIL þ LPS þ CD40L were measured 24 h later.
U0126 inhibited ERK1/2 phosphorylation by ;60% (Figure
3A), and the same compound reduced the IL-10 responses to
both M-gp120 (by 70%) and TNILþLPSþCD40L (by ;90%)
(Figure 3B). SB 203580 had a negligible effect on M-gp120-
stimulated IL-10 production but did inhibit the IL-10
response to TNIL þ LPS by 70% (Figure 3B).
In view of the reciprocal effects of the ERK1/2 pathway on
IL-10 and IL-12 production by DCs [30,31], we also measured
the IL-12p70 responses to M-gp120 and to TNIL þ LPS. M-
gp120 triggered a very slight increase in IL-12p70 expression.
In contrast, TNIL þ LPS activated a substantial IL-12p70
response that was completely blocked by SB 203580 but
potentiated (4.7-fold) by U0126, a pattern consistent with a
previous report [31]. Neither inhibitor, by itself, activated IL-
10 or IL-12p70 production (Figure 3B).
Together, the use of signaling inhibitors implies that ERK1/
2 activation is required for IL-10 production by MDDCs in
response to either M-gp120 or TNIL þ LPS.
HIV-1 gp120 Impairs iMDDC Maturation
We used immunophenotypic analyses to investigate
whether gp120 affects iMDDC maturation. Neither M-gp120
nor D-gp120 induced iMDDCs to mature in the absence of
TNIL þ LPS þ CD40L; the cell-surface expression of no
maturation marker changed by more than 1.5-fold (unpub-
lished data). However, expression of CD80 was reduced by 3-
fold, CD83 by 7-fold, and CD86 by 2-fold when iMDDCs were
incubated with M-gp120 together with TNILþLPSþCD40L,
compared with when the cells were matured with TNILþLPS
þ CD40L alone. DC-SIGN expression was 2- to 3-fold greater
on MDDCs treated with TNIL þ LPS þ CD40L plus M-gp120
than on cells receiving only TNIL þ LPS þ CD40L, but MR
expression was unchanged. D-gp120 did not mimic the effects
of M-gp120 on the expression of CD80, CD83, CD86, and DC-
SIGN, implicating an MCLR(s) as a mediator of these effects
of gp120 (Figure 4). Furthermore, gp120 impaired the
maturation of iMDDCs from both IL-10-responding and
non-responding donors. The reduced expression of CD80,
CD83, CD86, and the increased expression of DC-SIGN did
not correlate with IL-10 secretion 48 h after gp120 addition
among the 15 donors tested, of which nine were IL-10
responders, six non-responders. There were no correlations:
r
2 ¼ 0.05 for CD80 fold-decrease versus IL-10; r
2 ¼ 0.02 for
CD83 fold-decrease versus IL-10; r
2 ¼ 0.00004 for the fold-
increase in DC-SIGN expression versus IL-10. The reduction
in CD86 expression also did not correlate with IL-10, r
2 ¼
0.00003.
The interaction of gp120 with an MCLR(s) therefore
partially blocks the TNILþLPSþCD40L-induced maturation
of iMDDCs that normally leads to increases in CD80, CD83,
and CD86 expression and a reduction in DC-SIGN expres-
sion. These events occur irrespective of whether the gp120-
treated cells produce IL-10.
HIV-1 gp120 Inhibits the Ability of mMDDCs to Induce T
Cell Proliferation
We next explored whether the effects of gp120 on MDDC
maturation (and cytokine production, see Supporting In-
formation) would affect their ability to stimulate the
proliferation of allogeneic T cells. To do this, M-gp120 or
D-gp120 (JR-FL) was added to iMDDCs simultaneously with
TNIL þ LPS (i.e., on day 6 from the start of the MDDC
culture). Inﬂuenza virus HA was used as a control antigen,
also given simultaneously with TNILþLPS. After the iMDDCs
had been cultured with the various stimuli for 48 h, the cells
Figure 3. Involvement of the ERK1/2 and p38 MAP Kinase Signaling
Pathways in the Induction of IL-10 and IL-12p70 by gp120 and TNILþLPS
(A) Day-6 MDDCs were incubated with or without JR-FL M-gp120 or D-
gp120 (3 lg/ml), or with TNIL þ LPS, for 10 min before pERK1/2 (upper
panel) and p-p38 levels (lower panel) were measured by ELISA (black
bars). The white bars show the effects of adding the pERK1/2 inhibitor
UO126 (5 lM) or the p38 inhibitor SB 203580 (10 lM) 1 h before the
gp120s or TNIL þ LPS. The bars represent the mean values 6 SEM for
data derived from four different donors.
(B) The experimental design was based on that used for (A), except that
the iMDDCs were incubated with or without UO126 or SB 203580 for 1 h
prior to the addition of M-gp120 or TNIL þ LPS þ CD40L and continued
incubation for 24 h. IL-10 (upper panel) or IL-12p70 (lower panel)
production was measured by ELISA after 24 h. The bars represent the
mean values 6 SEM for data derived from five different donors, which
were not the same as the ones used in (A).
doi:10.1371/journal.ppat.0030169.g003
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selected for CD8, CD14, CD16, CD19, CD36, CD56, CD123,
TCRc/d, and CD235a. CFSE-labeled, allogeneic CD4
þ T cells
were then added (the ratio of 1/10 was optimized for
detection of T cell proliferation) for a 5-d co-culture (i.e.,
from days 8–13 from the start of the MDDC culture). T cell
proliferation was measured as the proportion of CFSE-
negative cells. Flow-cytometric histograms supporting the
data presented below are shown in Figure S5.
MDDCs treated with gp120 in the absence of TNIL þ LPS
did not stimulate T cell proliferation (Figure 5A). However,
exposing the TNIL þ LPS-stimulated MDDCs to M-gp120 for
24–48 h reduced their ability to stimulate T cell proliferation
by ;65%. D-gp120 was less inhibitory, the ;30% decrease
being little different from the ;20% decrease seen with the
HA control antigen. M-gp120 depressed proliferation sig-
niﬁcantly more than did D-gp120 (one-tailed Mann-Whitney
U test, n ¼ 15, p , 0.0001). MDDCs from all 15 donors tested
(ten IL-10 responders, ﬁve non-responders) behaved similarly
in the T cell proliferation assay; the relative proliferation of
CD4
þ T cells in co-cultures with M-gp120 þ TNIL þ LPS-
treated MDDCs varied in a narrow range (60%–85%
reduction in proliferation) over a broad range of IL-10
responses (0–420 pg/ml) (Figure 5B). Overall, there was no
Figure 4. Gp120 Impairs iMDDC Maturation via Interaction with an MCLR(s)
The maturation status of MDDCs was evaluated after treatment for 48 h (days 6–8) with TNILþLPSþCD40L 6 3 lg/ml of JR-FL M-gp120 or D-gp120.
The cell surface expression of CD80, CD83, CD86, DC-SIGN, and MR on CD11cþ cells was measured by flow cytometry as described in Supporting
Information.
(A) The histograms show expression of the surface markers on MDDCs from one donor whose expression marker response to gp120 was of average
magnitude. The grey shaded profiles depict the use of isotype control mAbs, the other profiles were derived using the various specific test mAbs. The
black curves represent control MDDCs; red curves, MDDCs treated with TNILþLPSþCD40L; blue curves, TNILþLPSþCD40LþD-gp120; green curves,
TNIL þ LPS þ CD40L þ M-gp120.
(B) The average fold-changes (for 14 or 15 donors) in MFI values for MDDC cell-surface marker expression are depicted. The background MFIs obtained
with the respective isotype controls were subtracted from MFIs for all conditions. Then the ratios of MFI for presence of gp120 over the MFI for absence
of gp120 were calculated. For each marker, the MFI value derived from MDDC matured with TNILþLPSþCD40L alone is thus defined as 1.0 (log ratio¼
0). The means of the 10-logarithms of the ratios for all donors were calculated. The mean log MFI ratio 6 SD for cells also treated with either M-gp120
(black bars) or D-gp120 (white bars) are plotted relative to this baseline value corresponding to TNIL þ LPS þ CD40L alone.
doi:10.1371/journal.ppat.0030169.g004
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treated, TNIL þ LPS-stimulated MDDCs on day 8 and the
inhibition of subsequent T cell proliferation (% CFSE
dilution versus IL-10, r
2 ¼ 0.0008). The lack of effect of IL-
10 is not surprising because both cytokines and any stimulus
for their continued secretion are washed out of the MDDC
cultures before the T cells are added. However, the principal
point is that, as with maturation marker expression, the
MDDC phenotype is adversely affected by gp120 treatment,
whether or not the cells have an immediate IL-10 response.
We also found that JR-FL and KNH1144 gp120s each
caused a ;70% reduction in the capacity of LPS þ TNIL-
stimulated MDDCs from four donors to induce T cell
proliferation (similarly to what is shown for JR-FL gp120 in
Figure 5A, unpublished data). Since KNH1144 gp120 does not
induce IL-10 secretion from MDDCs (Figure 1C), this experi-
ment corroborates the ﬁnding that the anti-proliferative
effect is independent of IL-10 from MDDCs (Figure 5B). It
also conﬁrms that KNH1144 gp120 is biologically active in the
MDDC system despite its inability to induce IL-10 expression.
We measured the concentrations of both IL-10 and IL-
12p70 in the various MDDC-T-cell co-cultures on day 13
(Figure 5C). IL-10 concentrations varied by ,5-fold overall,
the co-cultures with MDDCs exposed to M-gp120 þ TNIL þ
LPS containing the highest level (280 6 45 pg/ml). The IL-10
response to M-gp120 þ TNIL þ LPS was signiﬁcantly higher
than to D-gp120 þ TNIL þ LPS (one-tailed Mann-Whitney U
test, n ¼ 5, p ¼ 0.028). IL-12p70 concentrations varied much
more substantially. They were very low (,10 pg/ml) in co-
cultures containing MDDCs treated with M-gp120, D-gp120,
or HA in the absence of TNIL þ LPS. When TNIL þ LPS was
used to mature the MDDCs, IL-12p70 concentrations reached
200 6 22 pg/ml. The inclusion of D-gp120 or HA caused a
modest (;2-fold) reduction, but when M-gp120 was used only
baseline levels of IL-12p70 were produced (7.2 6 1.7 pg/ml).
The IL-12p70 response to M-gp120 þ TNIL þ LPS was
signiﬁcantly lower than to D-gp120þTNILþLPS (one-tailed
Mann-Whitney U test, n ¼ 5, p ¼ 0.0040). Thus, compared to
the use of TNIL þLPS alone, exposure of the MDDCs also to
M-gp120 caused a 76-fold increase in the IL-10/IL-12p70 ratio
in the co-cultures, whereas the use of D-gp120 and HA caused
only 2.4- and 1.3-fold increases, respectively. Moreover, the
pattern of IL-12p70 responses in the various co-cultures
(Figure 5C, lower panel) was similar to the pattern of T cell
proliferation in the same cultures (Figure 5A). IL-4 was also
measured, the concentrations ranging from 5–15 pg/ml in the
different co-cultures, with no obvious pattern of response
detectable (unpublished data).
In conclusion, MDDCs matured in the presence of gp120
are functionally impaired, irrespective of whether they
secrete IL-10 soon after gp120 binds to MCLRs.
Figure 5. Treatment with gp120 Inhibits MDDC-Induced T Cell
Proliferation
(A) Day-6 MDDCs were incubated for 48 h with or without TNIL þ LPS
and/or JR-FL M-gp120, D-gp120, or influenza HA as specified on the x-
axis. The MDDCs were then co-cultured for 5 d with CFSE-labeled CD4þT
cells before determination of the extent of the allogeneic mixed T
lymphocyte reaction on day 13. Relative CD4
þ T cell proliferation was
calculated by first subtracting the background value for CFSE-negative
cells obtained using unstimulated iMDDCs (9.95% 6 0.70%, n¼15) from
the value obtained when the MDDCs were stimulated with TNIL þ LPS
(46.4% 6 1.54%, n¼15). The net value was defined as 100% and used for
normalization. The bars represent the mean values 6 SD for data derived
from 15 donors (except for influenza HA; ten donors) tested in 15
independent experiments. The superantigen SEB served as a positive
control for CD4þ T cell stimulation in the absence of any MDDCs; CFSE
dilution in response to SEB was 130% 6 2.9% (n ¼15) of that seen with
TNIL þ LPS (unpublished data).
(B) The extent of T cell proliferation in co-cultures (as in A) containing
iMDDCs exposed to M-gp120 þ TNIL þ LPS þ CD40L is plotted as a
function of the IL-10 response of the iMDDCs to M-gp120 after 24 h.
There was no correlation for iMDDCs from 15 donors (r
2 ¼ 0.0008).
(C) In a subset of the experiments shown in (A), extracellular cytokine
levels were measured at the end of the MDDC-T cell co-culture (i.e., on
day 13). The bars represent the mean values 6 SEM from five different
donors. Upper panel, IL-10; lower panel, IL-12p70.
doi:10.1371/journal.ppat.0030169.g005
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We show here that exposure to HIV-1 gp120s can impair
the maturation of human iMDDCs, triggering cells from some
donors to secrete IL-10, a cytokine generally associated with
immunosuppressive responses [23]. Irrespective of whether
they secrete IL-10, the gp120-treated MDDCs mature in-
efﬁciently in response to conventional stimuli, and their
abilities to stimulate the proliferation of T cells in co-cultures
are impaired. The latter defect could be due to their reduced
expression of CD80, CD83, and CD86 and hence a weakening
of the co-stimulatory interactions with T cells that drive the
latter’s proliferation. The reduction in IL-12p70 levels (and a
substantial increase in the IL-10/IL-12p70 ratio) in the co-
cultures may also be relevant [33].
These various effects are a consequence of an interaction
between the mannose components of gp120 glycans and an
MCLR(s), in that the enzymatic removal of mannoses from
gp120 reduced or prevented their occurrence. We also
probed the IL-10 response to gp120 using various blocking
ligands. Thus, CV-N and the 2G12 mAb bind to gp120
mannoses, and each inhibited IL-10 induction, whereas
inhibitors of gp120 binding to CD4, CCR5, or CXCR4 were
ineffective. Furthermore, mannan, another MCLR ligand,
activated IL-10 expression. Also relevant is that gp120
induces IL-10 expression in immunized mice [11]: Gp120
cannot bind to murine CD4, CCR5, or CXCR4, or to the
murine MCLR with the greatest sequence similarity to human
DC-SIGN [34]. However, ﬁve murine DC-SIGN homologues
have been described [35], so it is possible that some of them
do bind gp120. The inﬂuenza HA Env protein does not
induce IL-10 expression either in the immunized mice or in
our own in vitro experiments; HA binds the MR [36] but not
DC-SIGN or DC-SIGNR [37].
Several different MCLRs are known or potential binding
sites for gp120 on DC, including DC-SIGN, langerin, and the
MR [38]. We found that mAbs to DC-SIGN and the MR
together completely ablated the IL-10 response to gp120,
while the anti-DC-SIGN mAb was partially inhibitory by itself.
Furthermore, there was a correlation between the extent of
IL-10 production and the level of DC-SIGN expression on the
MDDCs. Together, these observations strongly suggest a role
for DC-SIGN binding in the IL-10 response to gp120 but
other MCLRs, particularly the MR, also seem likely to be
involved.
M-gp120, but not its demannosylated derivative, activated
ERK1/2 phosphorylation, and the ERK1/2 inhibitor U0126
inhibited the IL-10 response to M-gp120. These ﬁndings
imply that the gp120-MCLR interaction triggers the ERK1/2
signaling pathway and that this is necessary for activation of
IL-10 expression. Whether the same pathway mediates the
other MDDC responses to gp120 remains to be determined.
This conclusion is consistent with earlier reports on the
role of the ERK1/2/MAP kinase pathways in the IL-10
response when DCs are activated by other stimuli, including
TLR ligands and DC-SIGN-speciﬁc antibodies [30–32]. The
binding of pathogens, including HIV-1, to DC-SIGN has also
been shown to activate the Raf-1-acetylation-dependent
signaling pathway [39]. The gp120-treated MDDC from about
half the 71 donors we studied secreted elevated amounts of
IL-10, and the response pattern was consistent when 11
donors were re-tested a month later. Hence, genetic or other
invariable factors and not, for example, an inter-current
infection seem most likely to determine whether a donor’s
MDDCs respond to gp120 in this way, or not. Complex host
genetic factors inﬂuence IL-10 gene regulation [23,40–42],
suggesting one area for further study. The genetics of MCLR
expression might also be relevant; different MCLRs might be
involved to different extents on MDDCs from different
donors. DC-SIGN expression varies considerably in rectal
tissue samples from different individuals and has been
associated with local increases in the IL-10/IL-12 ratio [33].
Nonetheless, the IL-10 response to gp120 is only one marker
for the adverse effect of this ligand on MDDCs; whether or
not a donor’s cells secreted IL-10 in response to gp120, they
were functionally impaired, matured poorly, and were unable
to efﬁciently stimulate T cell proliferation.
We also observed that both the concentration and the
identity of the gp120 protein inﬂuenced the IL-10 response.
Two of the three tested gp120s (JR-FL and LAI) triggered IL-
10 release from MDDCs of responsive donors, whereas gp120
from KNH1144 did not. We do not yet know why KNH1144
differs from the other two gp120s in this regard. The most
likely explanation is that there are subtle differences between
the gp120s in exactly how they interact with one or more
MCLR, and that the IL-10 response is particularly sensitive to
a speciﬁc, but as yet uncharacterized, facet of these
interactions. Differences in how diverse HIV-1 virions and
gp120 proteins interact with DC-SIGN have been reported,
although the variations in gp120 structure that affect the
interaction have still to be fully deﬁned [43] (M. Jansson,
personal communication). A sequence alignment of the JR-
FL, LAI, and KNH1144 gp120 proteins, with emphasis on the
positions of N-linked glycans, suggests a number of poten-
tially relevant differences (Figure S6). Since understanding
the molecular basis for the lack of IL-10 induction might help
in the design of new Env-based immunogens, mutagenesis
studies that focus on the N-linked glycans of JR-FL and
KNH1144 could be informative, as might the use of addi-
tional gp120s that vary in sequence and that are expressed in
cell types that lead to differences in glycosylation patterns. It
is important, however, that any such reagents be highly
puriﬁed free of the LPS contaminants that are common in
most commercial gp120 preparations and in some others
made under non-GMP conditions. The same constraints
apply to the use of inactivated HIV-1 virions. We have not
yet tested virions, as the focus of the present study is on
soluble Env proteins that are (or were) vaccine candidates.
Moreover, virions contain several TLR activators that might
induce different cytokine responses that complicate any
analysis of the effects of the Env component [44–46].
Several earlier studies have shown that gp120 and
inactivated HIV-1 virions can have complex effects on
MDDCs and their interactions with T cells and on cytokine
secretion by both cell types in vitro. Thus, compared to LPS,
R5, and X4 gp120s both stimulated much less IL-12
production from MDDCs, but without IL-10 release [19]. Just
as we have observed, gp120-treatment impaired MDDC
maturation in response to classical stimuli, reducing their
ability to stimulate T cells, but unlike our results, CD80,
CD83, and CD86 were up-regulated on the gp120-treated
cells [19]. In another study, exposure of MDDCs to X4 gp120
up-regulated CD80 and CD86 and down-regulated MR, with
increased secretion of IL-10, IL-12, IL-18, and TNF-a [47].
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infected MDDCs, associated with an inability of the cells to
secrete IL-12 in response to CD40L [48]. The receptor
interactions of gp120 most responsible for its various
biological effects were not determined in these various
studies. Gp120 is also known to stimulate IL-10 release from
monocyte/macrophages in vitro [17,18,20,22,24]. There is one
report that MDDCs undergoing continued stimulation with
GM-CSF and IL-4 did not secrete IL-10 in response to gp120,
although differences in the experimental conditions are
probably responsible, and the donor- and gp120-dependent
variation we now describe may also be relevant [49].
Our observations are consistent with a mounting body of
evidence on the biological effects of ligating MCLRs on DCs.
Thus, HIV-1 BaL and a speciﬁc DC-SIGN mAb have recently
been shown to activate Rho-GTPase-dependent signals via
DC-SIGN that favor the formation of DC-T-cell synapses and
HIV-1 infection of the T cells [50]. The same signaling events
also induced the ATF3 transcription factor that suppressed
TLR-response genes, attenuating the LPS responses of the
cells by reducing IL-12p70 secretion and down-modulating
CD86 and HLA-DR. Thus, as we observed with gp120, the
anti-DC-SIGN mAb induced a semi-immature state in the
MDDCs, which failed to stimulate T cell proliferation
effectively [50]. Indeed, the binding of an antibody to DC-
SIGN was previously found to activate ERK-1/2 but not p38
[32], similar to what we have observed with gp120. Cross-
linking the MR via a speciﬁc mAb can have a broadly similar
effect on the MDDC phenotype [51]. It will be worth studying
whether the downstream signals activated by the MCLR MAbs
are also triggered by gp120. Of further note is that an
allergenic glycoprotein from peanuts also induces ERK1/2
signaling in MDDCs via DC-SIGN, but up-regulates MHC and
co-stimulatory molecules and thereby increases the ability of
the MDDCs to activate T cell proliferation [52]. Thus, there
may be considerable subtleties to how different glycoproteins
and mAbs bind to DC-SIGN and other MCLRs on the MDDC
surface, and the intracellular consequences of these inter-
actions. Most mAbs to DC-SIGN or the MR do not induce
transmembrane signals, but some do [50,51]; likewise, some
gp120s induce IL-10 expression, others do not. One relevant
point may relate to how an MCLR ligand is mannosylated:
adding O-linked mannoses to ovalbumin increases lympho-
proliferation in mixed BMDC-T-cell cultures while N-linked
mannoses have the opposite effect, and mannosylated
ovalbumin impaired IL-12p70 secretion [53]. Most mannose
residues on gp120 are N-linked [54], but the relative amounts
of N- and O-linked moieties could vary between strains and
inﬂuence the overall signaling patterns that are activated.
Other pathogens also use mannose moieties to suppress
immune responses, again via binding to MCLRs. For example,
the M.Tb cell wall component ManLAM binds to DC-SIGN at
a similar site to gp1209s, induces IL-10 production, impairs
DC maturation, and suppresses the host immune response to
this pathogen [55,56]. Some lactobacilli do much the same,
although without the involvement of mannose residues [57].
Although DC-SIGN, and MCLRs in general, are important
sentinels for the presence of pathogens, some organisms may
be able to subvert at least some of the natural functions of
these receptors for their own purposes [58]. DC-SIGN, in
particular, may be considered as an unconventional PRR
(pattern recognition receptor) that drives TH2 and Treg
responses [32,58]. Silencing SOCS-1 in DC has been shown
to reduce the suppressive effect of gp120 on the production of
pro-inﬂammatory cytokines in vitro [59]. Mice immunized
with gp120-pulsed, SOCS-1-silenced DC produced higher and
more sustained titers of anti-gp120 antibodies, and TH1-
polarized cellular responses to gp120 [59]. Conversely, over-
expressing SOCS-3 in murine DC increased IL-10 expression,
and SOCS-3-transduced DC primed a TH2-dominant re-
sponse when co-cultured with CD4
þ T cells in vitro [60].
Perhaps these observations are linked mechanistically to ours?
Caution must always be taken when extrapolating from cell
culture systems to the more complex environment of tissues
in vivo where the DC phenotype differs from the MDDCs we
have used here and where gp120 concentrations are hard to
estimate [16,61]. We note, however, that DCs and T cells
isolated from HIV-1-infected persons can have aberrant
phenotypes that are broadly similar to those of the gp120-
exposed MDDCs that we have studied in vitro [62]. In
particular, elevated numbers of tolerogenic semi-mature
DCs, and FOXP3
þ CD4
þ regulatory T cells, have been
observed in lymph nodes of HIV-1-infected people [63].
Moreover, high levels of IL-10, accompanied by a reduction in
IL-12, can be found in plasma during primary HIV-1
infection [64]. IL-10 can have a substantial effect on the
course of viral infections [65]. Thus, blocking IL-10 signaling
by antibodies to its receptor promotes the clearance of
lymphocytic choriomenigitis virus and prevents the establish-
ment of a persistent infection [66,67]. Perhaps similar events
are involved in persistent infection by HIV-1? Thus it is
possible that, during primary infection, env-gene products
could help suppress the development of anti-HIV-1 immune
responses at this critical time, particularly as virion-associ-
ated gp120 is more efﬁcient than free gp120 at inducing
various signaling events [68]. If so, the retention of high
mannose moieties on the Env complex would be yet another
defense HIV-1 uses in its battle with host immunity. We
previously noted that the presence of mannoses on Env is
paradoxical because they might facilitate virion clearance
from the blood [25]: Counter-functions would justify their
retention.
Our observations could help understand the outcome of
immunizing with Env-based antigens, and perhaps why
different individuals respond to these vaccines with Ab titers
that can vary over a several-log range [5–9]. When milligram
amounts of gp120 are delivered in a bolus into tissues, local
concentrations are likely to be high enough to affect the
performance of various immune system cells, including DCs,
during the earliest, formative stages of the immune response
[16]. In a comparative DNA and protein immunization study
in mice, the antibody and cytokine responses to gp120 were
strongly TH2-polarized, whereas responses to HA were TH1-
biased. Furthermore, the TH2 bias of the anti-gp120 response
did not occur in IL-10 knock-out mice [11]. Although T-
helper phenotypes are more complex in humans than mice,
the responses to gp120, during infection and after vaccina-
tion, do appear to be TH2-biased [12–15]. Including Env in
multi-component HIV/SIV vaccines can sometimes be dele-
terious to protection [69,70]. Also, immunizing horses with
insect cell–expressed Env proteins (which are enriched for
high-mannose moieties) from Equine Infectious Anemia
Virus (EIAV) enhanced post-immunization infection with
EIAV, whereas EIAV Env proteins expressed in mammalian
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pressed gp120 proteins were also comparatively poor
immunogens in mice, because of a limited ability to induce
T-helper responses [9].
Any vaccine-related, adverse inﬂuences of the high-
mannose moieties on gp120 glycans could be overcome by
treating gp120 with a mannosidase enzyme. We are now
investigating whether this strategy improves the immunoge-
nicity of HIV-1 Env proteins. Deleting a subset of N-linked
glycans altered the IgG isotype proﬁle of the antibody
response to the HCV E1 protein in immunized mice and
improved its immunogenicity overall [74]. Of course, raising
higher titers of antibodies and/or reducing the rate of decay
of the antibody response to HIV-1 Env will achieve little if
those antibodies are non-neutralizing. Our hope, however, is
that a general increase in the immunogenicity of Env proteins
could facilitate the development of otherwise sub-threshold
NAb responses, and/or enable lower amounts of Env trimers
to be used. Combining the mannose-removal technique with
other strategies intended to increase the immunogenicity of
NAb epitopes should also be possible. Several other vaccine
antigens that are considered to be problematic from the
immunogenicity perspective, such as RSV F, RSV G, CMV gB,
and Ebola GP, are also highly glycosylated and/or can bind to
MCLRs (S. Plotkin and B. Graham, personal communication)
[75–77]. Whether these proteins might also contain high-
mannose moieties or other carbohydrate structures that can
interact with MCLRs and that could be removed enzymati-
cally is worth considering.
Materials and Methods
Recombinant proteins and cytokines. Recombinant, CHO-cell
expressed monomeric gp120s from HIV-1 JR-FL, LAI, and
KNH1144 were manufactured at Progenics, as previously described,
under GMP conditions [78]. The concentration of the gp120 stocks
was 1 mg/ml, with Endotoxin contamination ,3 EU/ml. Gp120 was
added to target cells at 3 lg/ml (25 nM), except when otherwise
speciﬁed. Insect cell–expressed inﬂuenza hemagglutinin (HA) protein
(100 lg/ml) was purchased from Protein Sciences Corporation and
used at 3 lg/ml (Endotoxin ,10 EU/ml, no fungal or bacterial
contamination).
LPS from Salmonella Typhimurium (1 mg, Sigma) was used at 100 ng/
ml. Recombinant soluble CD40L (50 lg, Bristol-Myers Squibb) with an
Endotoxin level of , 0.1 ng per lg (1 EU/lg) was used at 1 ng/ml; TNF-
a and IL-1b (R&D Systems) at 25 ng/ml and 10 ng/ml, respectively.
Inhibition of gp120-induced IL-10 production. iMDDCs were
incubated for 1 h at 37 8C with various agents before gp120 was
added. The anti-DC-SIGN mAb AZN-D1 (Beckman Coulter), the
isotype control mouse IgG1 (Clone 2T8-2F5, Beckman Coulter), the
anti-mannose receptor (MR; CD206) mAb Clone 15–2 (Cell Sciences),
and the isotype control mouse IgG1, j (Clone MOPC-21, BD
Pharmingen) were each used at 40 lg/ml, alone or in combination.
The CCR5 inhibitor AD101 (from J. Strizki, Schering Plough Research
Institute)[79] and the CXCR4 inhibitor AMD3100 (from G. Bridger,
AnorMed Incorporated) [80] were each used at 10 lM. Mannan
(Sigma) was added at 30 lg/ml.
Alternatively, gp120 was mixed with sCD4 (Progenics) [81], mAb
b12 (from D. Burton, Scripps) [82], mAb 2G12 (from H. Katinger,
University of Vienna) [83], each at 25 lg/ml, or with cyanovirin-N
(CV-N; from R. Shattock, St. George’s, London) [26] at 5 lg/ml for 1 h
at room temperature on a roller before addition to the cells.
Mannosidase treatment of recombinant gp120. The mannose
residues were removed from JR-FL gp120 to make demannosylated
gp120 (D-gp120) as follows [25]. Aliquots of gp120 (120 lg) were
incubated for 16–18 h at 37 8C with no enzyme (mock treatment; M-
gp120) or with a-(1,2,3,6)-mannosidase (Jack Bean, GKX-5010; 25
Units/mg, 0.14 Units/lg gp120; from ProZyme Incorporated) in a ﬁnal
volume of 1.2 ml, in the presence of protease inhibitors (Roche). A
control incubation of enzyme-only (no gp120) was also performed.
The samples were desalted into half-strength PBS (1/2 PBS) using PD-
10 desalting columns (GE Healthcare) and concentrated to 1 ml using
Vivaspin 30k MWCO 6 ml spin concentrators (Vivascience). After
addition of 1 volume of 1/2 PBS, each sample was processed using the
Endofree Red 5/1 Endotoxin removal kit (Profos AG). The ﬁnal
volumes of the D-gp120 and M-gp120 preparations after endotoxin
removal were ;2 ml, with endotoxin levels ,8–20 EU/mg and gp120
concentrations 60 lg/ml. SDS-PAGE and western blot analyses were
performed using mAbs 2G12 and CA13 (ARP3119).
ELISA for gp120-binding ligands. gp120 proteins were captured
onto ELISA wells via sheep antibody D3724 to the gp120 C-terminus,
and mAb or CD4-IgG2 binding was assessed essentially as described
previously [84]. For DC-SIGN binding to the captured gp120, the
standard procedure was adapted as follows: The plates were washed
three times with TSM (20 mM Tris, 150 mM NaCl, 1 mM CaCl2,2m M
MgCl2), followed by incubation with TSM/1% BSA for 30 min. After
three washes with TSM, DC-SIGN-Fc (a gift from T. Geijtenbeek [85])
in TSM was added for 2 h, with or without a prior incubation for 15
min with EGTA (10 mM) or mAb AZN-D1 (10 lg/ml). The plates were
washed ﬁve times with TSM/0.05% Tween, then bound DC-SIGN-Fc
was detected with peroxidase-labeled goat anti-human Fc (1:3,000) in
TSM/0.05% Tween using standard conditions.
Cell culture. Peripheral blood mononuclear cells (PBMC) were
isolated from buffy coats (New York Blood Center or Research Blood
Components) by Ficoll density gradient centrifugation. Monocytes
were isolated to high purity (.98%) by magnetic cell sorting with
anti-CD14-coated beads according to the manufacturer’s recommen-
dations (Miltenyi Biotec). The percentage of CD14
þ monocytes
among the cells sorted from PBMC was determined by ﬂow cytometry
and always exceeded 98%. The CD14
 fraction was frozen and used as
the source of T cells for MDDC-T cell co-cultures. The monocytes
were subsequently cultured for 6–8 d in complete culture medium
(RPMI 1640, GIBCO/Invitrogen) containing 1 mM sodium pyruvate,
0.1 mM nonessential amino acids, 2 mM L-glutamine, 25 mM HEPES,
100 U/ml penicillin, 100 lg/ml Streptomycin (all obtained from
GIBCO/Invitrogen), and supplemented with 5% Human AB serum
(Sigma) (R-5), 1,000 U/ml GM-CSF (Leukine, Sargramostim), and 1,000
U/ml of recombinant human IL-4 (R&D Systems) at 37 8Ci na n
atmosphere containing 5% CO2. Every 2 d, 400 ll of medium were
gently removed from each well and replaced by 500 ll of fresh
medium containing the appropriate cytokines.
MDDC maturation. iMDDCs were either used without maturation
or were differentiated for 24 h or 48 h with TNIL þLPS 6 CD40L, a
mixture of inﬂammatory cytokines: 25 ng/ml of TNF-a and 10 ng/ml
of IL-1b (TNIL), and LPS (10 ng/ml or 100 ng/ml) 6 CD40L (1 lg/ml).
Because elevated CD83 expression on MDDCs (a response to TNF-a)
is necessary but not sufﬁcient for IL-12 responses [86], CD40L, a
strong inducer of IL-12, was included in all experiments in which IL-
12p70 was measured. The ﬂow-cytometric analysis of maturation
markers is described in Supporting Information.
Reverse transcriptase-PCR. iMDDC were incubated with and
without gp120 (3 lg/ml) for various times at 37 8C, and analyzed for
the expression of IL-10 mRNA by reverse transcriptase (RT)-PCR.
Total RNA was extracted from 1 3 10
6 iMDDCs by using the
Absolutely RNA Miniprep Kit (Stratagene) according to the manu-
facturer’s manual. The isolated total RNA (2 ll) was used for synthesis
of cDNA using the Super Script III First-Strand Synthesis System for
RT-PCR ( Invitrogen). Human IL-10 and b-actin transcripts were
ampliﬁed using the following primers: IL-10 forward 59-ATGCCC-
CAAGCTGAGAACCAAGACCCA-39 and reverse 59-
TCTCAAGGGGCTGG GTCAGCTATCCCA-39. The PCR product is
352 bp and was veriﬁed by sequencing. The b-actin primers used
were: forward 59- TCCTGTGGCATCCACGAAACT-39 and reverse 59-
GAAGCATTTGCGGTGGACGA T-39. Their ampliﬁcation product of
315 bp was also veriﬁed by sequencing. The annealing temperature
for gradient PCR detection of IL-10 transcripts was optimized so as to
avoid cross-reaction with IL-4, IL-6, IL-12p35, and IL-12p40.
Cytokine or chemokine measurements. Puriﬁed monocytes were
cultured in RPMI 1640 supplemented with 5% human AB serum,
1,000 U/ml GM-CSF, and 1,000 U/ml IL-4 for 6 d in order to produce
iMDDCs, then washed thoroughly. The cells were aliquoted at various
densities from 5310
5 to 1310
6 cells/ml into 24-well plates, and then
stimulated as described in Results. Cytokine IL-10 and IL-12p70
concentrations in cell-free culture supernatants were measured by
ELISA using OptEIA kits from BD Pharmingen, as per the
manufacturer’s protocol. The detection sensitivity for each cytokine
was 4 pg/ml. Chemokine CCL17/TARC, CCL22/MDC, CCL19/MIP-3b,
and CXCL10/IP10 were measured by ELISA assays using DuoSet
ELISA kits from R&D Systems.
MAPK assay. For analysis of MAPK signaling pathways, day-6
iMDDCs were collected, washed three times with warm PBS, and then
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stimuli. The cells were then incubated in the presence or absence of
gp120 or TNIL þ LPS for various times. Where indicated, an MEK
inhibitor (U0126, 5 lM) or a p38 inhibitor (SB 203580, 10 lM) was
added to the cultures 1–2 h before gp120 or TNIL þ LPS. The cells
were harvested and washed twice with cold PBS, then centrifuged into
a pellet, and resuspended in 300 ll of lysis buffer (1% Nonidet P-40,
0.1% SDS, 0.5% sodium deoxycholate in PBS) containing PMSE (100
lg/ml) and a protease inhibitor mixture (500 lg/ml) (Roche
Diagnostics). In some experiments, the supernatants were also
collected and stored at  80 8C for later analysis of cytokine content.
The total protein concentration of the cell pellets was measured using
the bicinchoninic acid assay (Pierce). Samples containing 30 lgo f
total protein were heated at 100 8C for 5 min in the presence of DTT,
then the following assay kits were used according to the manufac-
turer’s instructions (Calbiochem): p38[TOTAL] ELISA kit;
P38[pTpY180/182] ELISA kit; ERK1/2[TOTAL] ELISA kit; ERK1/2
[pTpY185/187] ELISA kit.
T cell proliferation assay. Allogeneic CD4
þT cells were obtained by
negative selection with magnetic beads and washed twice with PBS
(see Supporting Information); the cells were then incubated with 2.5
lM carboxy-ﬂuorescein diacetate, succinimidyl ester (CFSE) (derived
from a 5-mM CFSE stock; Molecular Probes) for 15 min at room
temperature, with gentle agitation every 2–3 min [87]. The reaction
was quenched by the addition of an equal volume of RPMI 1640
containing 10% human AB serum followed by incubation for 5 min.
The cells were then washed with PBS three times and resuspended at
2 310
6 cells/ml in complete culture medium before use in experi-
ments. For the mixed T lymphocyte reaction assay, CFSE-labeled or
unlabeled allogeneic CD4þT cells were co-cultured with differentially
treated MDDCs at a 1/10 ratio for 5 d. (In preliminary experiments,
the DC:T cell ratio was varied over the range 1/10 2 to 1/102 in 10-fold
increments, for both iMDDCs and mMDDCs, the optimal ratio for
detecting T cell proliferation after 5 d of co-culture being 1/10.)
Proliferation of the CFSE-labeled naı ¨ve T cells was analyzed by ﬂow
cytometry [87]. Supernatants were collected from the co-cultures of
MDDCs with unlabeled allogeneic CD4
þ T-cells on day 5, for
measurement of cytokine levels by ELISA.
Statistical analysis. IL-10 measurements were subjected to the
D’Agostino and Spearman omnibus normality test. The data were not
uniformly normal. Hence, differences between groups were analyzed
by one-tailed Mann-Whitney U test. The a level was set to 0.05.
Correlations rather than regression analyses were performed since we
analyzed measured variables (IL-10 secretion, cell surface antigen
expression, and cell proliferation).
Supporting information. The derivation and phenotypic charac-
terization of the iMDDCs and mMDDCs, as well as the puriﬁcation of
CD4
þ T cells, are described in Text S1. We also show the time course
of IL-10 induction and Ab controls for the blocking of gp120-induced
IL-10 secretion. Furthermore, we describe the effects of mAbs to DC-
SIGN and MR on the expression of MDDC maturation markers, and
provide examples of ﬂow cytometric histograms illustrating inhib-
ition of T cell proliferation. The cytokine and chemokine responses
of gp120-treated MDDC are discussed.
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